With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Novavax faces a setback as the FDA requests an additional trial for COVID-19 vaccine approval. Read more here.

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...

The Department of Health and Human Services (HHS) and Secretary Robert F. Kennedy Jr. | As concerns about infectious disease ...

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...

Novavax's COVID-19 vaccine could soon receive full approval from the U.S. Food and Drug Administration (FDA), the company ...

In March, the federal government pulled back $11.4 billion in promised funding for state and community health departments.

Childhood vaccination rates have been falling in the United States, especially since the start of the COVID-19 pandemic.

The mRNA technology behind the Pfizer and Moderna vaccines are groundbreaking, but their potential goes way beyond COVID-19.

Rejoice, fellow vaccine enthusiasts-it looks like there's good news on the horizon for Novavax, everyone's favorite scrappy, ...

When COVID-19 first emerged, the U.S., under President Donald Trump, made an urgent bet on vaccines — and it paid off ...